Conditions:   Colorectal Neoplasms;   Effects of Chemotherapy;   Surgery;   Metastasis;   Local Neoplasm Recurrence
Interventions:   Drug: Irinotecan;   Drug: 5-fluorouracil;   Radiation: Local radiotherapy;   Procedure: R0 resection
Sponsor:   Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting - verified March 2014

Conditions:   Incurable Colorectal Cancer;   RAS-wild-type
Interventions:   Drug: Cetuximab;   Drug: irinotecan;   Drug: fluorouracil
Sponsors:   Shanghai Zhongshan Hospital;   Tianshu Liu
Recruiting - verified February 2014

Condition:   Glioblastoma Multiforme
Interventions:   Biological: ALECSAT;   Drug: Bevacizumab/Irinotecan
Sponsor:   CytoVac A/S
Recruiting - verified February 2014

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: FOLFOXIRI + Cetuximab;   Drug: FOLFOXIRI
Sponsor:   Sun Yat-sen University
Not yet recruiting - verified February 2014

Conditions:   Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions:   Biological: carboxylesterase-expressing allogeneic neural stem cells;   Drug: irinotecan hydrochloride;   Other: laboratory biomarker analysis
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Not yet recruiting - verified February 2014

Conditions:   Metastatic Cancer;   Unspecified Adult Solid Tumor
Interventions:   Drug: PARP inhibitor BMN-673;   Drug: temozolomide;   Drug: irinotecan hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   Jonsson Comprehensive Cancer Center;   Translational Research in Oncology-US (TRIO-US)
Not yet recruiting - verified January 2014

Conditions:   Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage I Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions:   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
Sponsors:   Yale University;   National Cancer Institute (NCI)
Recruiting - verified January 2014

Conditions:   Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum
Interventions:   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: 5-FU;   Drug: Irinotecan
Sponsors:   Weill Medical College of Cornell University;   Sanofi
Not yet recruiting - verified January 2014

Condition:   Colorectal Cancer
Interventions:   Drug: Dacomitinib;   Drug: PD-0325901;   Drug: Irinotecan;   Drug: Docetaxel;   Drug: Capecitabine
Sponsors:   The Netherlands Cancer Institute;   Pfizer
Recruiting - verified January 2014

Conditions:   Breast Cancer;   Ovarian Cancer;   Colon Cancer;   Lung Cancer;   Gastric Cancer;   Solid Tumors
Interventions:   Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: FOLFIRI
Sponsor:   AbbVie
Enrolling by invitation - verified January 2014

Condition:   Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
Intervention:   Drug: irinotecan Hydrochloride
Sponsor:   Liaoning Tumor Hospital & Institute
Not yet recruiting - verified January 2014

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: mFOLFIRINOX
Sponsors:   Sun Yat-sen University;   Yuhong Li
Recruiting - verified January 2014

Conditions:   Metastatic Pancreatic Ductal Adenocarcinoma (PDAC);   Pancreatic Cancer
Interventions:   Drug: anakinra;   Drug: Modified Folfirinox Regimen
Sponsor:   Baylor Research Institute
Recruiting - verified December 2013

Condition:   Colorectal Cancer
Interventions:   Drug: DEBIRI;   Device: LC Bead M1;   Procedure: TACE
Sponsor:   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified December 2013

Conditions:   Recurrent or Refractory Solid Tumors;   Ewing Sarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Osteosarcoma
Intervention:   Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
Sponsors:   Merrimack Pharmaceuticals;   South Plains Oncology Consortium (SPOC)
Not yet recruiting - verified December 2013

Conditions:   Astrocytoma, Oligoastrocytoma, Mixed;   Ganglioneuroma;   Glioma;   Ganglioglioma;   Glioblastoma Multiforme Glioma
Interventions:   Drug: Irinotecan;   Drug: Bevacizumab;   Device: FDOPA-PET/MRI imaging
Sponsor:   Washington University School of Medicine
Recruiting - verified December 2013

Conditions:   Colorectal Neoplasms;   Neoplasm Metastasis;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasms
Interventions:   Biological: Bevacizumab;   Drug: CPT-11 (Irinotecan);   Drug: 5-FU Bolus;   Drug: 5-FU Infusion;   Drug: l-LV (dl-LV);   Biological: bevacizumab;   Drug: CPT-11 (Irinotecan);   Drug: Capecitabine
Sponsor:   Epidemiological and Clinical Research Information Network
Not yet recruiting - verified November 2013

Condition:   Small Cell Lung Carcinoma
Interventions:   Drug: Irinotecan;   Drug: Cisplatin
Sponsor:   Third Military Medical University
Recruiting - verified October 2013

Condition:   First Line Metastatic Colorectal Cancer
Intervention:   Drug: Irinotecan
Sponsors:   Centre Jean Perrin;   Centre Jean Perrin
Active, not recruiting - verified October 2013

Condition:   Metastatic Pancreatic Adenocarcinoma
Interventions:   Drug: PEGPH20;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: Irinotecan;   Drug: 5-fluorouracil
Sponsors:   Southwest Oncology Group;   Southwest Oncology Group;   National Cancer Institute (NCI);   Halozyme Therapeutics
Not yet recruiting - verified October 2013